A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene).

Authors

Sean DeAngelo
Kailyn Mann DO, Lehigh Valley Health NetworkFollow
Muhammad Abdulbasit
Amy M. Ahnert MD, Lehigh Valley Health NetworkFollow
Deborah W Sundlof DO, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

12-14-2020

Abstract

Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who presented with accelerated atherosclerosis. His triglyceride level (TG) was greater than 1000 mg/dL, which rapidly improved with discontinuation of Targretin.

Volume

6

Issue

1

First Page

31

Last Page

31

ISSN

2057-3804

Published In/Presented At

DeAngelo, S., Mann, K. I., Abdulbasit, M., Ahnert, A., & Sundlöf, D. W. (2020). A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene). Cardio-oncology (London, England), 6(1), 31. https://doi.org/10.1186/s40959-020-00087-3

Disciplines

Cardiology | Medicine and Health Sciences

PubMedID

33308287

Peer Reviewed for front end display

Peer-Reviewed

Department(s)

Department of Medicine, Cardiology Division, Department of Medicine Faculty

Document Type

Article